A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Incyte Corporation
Incyte Corporation
Thomas Jefferson University
Incyte Corporation
Eilean Therapeutics
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Turin, Italy
Incyte Corporation
Merck Sharp & Dohme LLC
Incyte Corporation
University of Southern California
Incyte Corporation
University Hospital, Brest
University of Washington
M.D. Anderson Cancer Center
University of California, Irvine
University Hospital, Angers
Brigham and Women's Hospital
Massachusetts General Hospital
University of Miami
Icahn School of Medicine at Mount Sinai
University Hospital, Angers
Thomas Jefferson University
Constellation Pharmaceuticals
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Ohio State University Comprehensive Cancer Center
Hangzhou GluBio Pharmaceutical Co., Ltd.
PharmaEssentia
PharmaEssentia
PharmaEssentia
Barbara Ann Karmanos Cancer Institute
City of Hope Medical Center
RWTH Aachen University
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Italfarmaco
Icahn School of Medicine at Mount Sinai
National Cancer Institute (NCI)
AbbVie
University Hospital, Angers
Tongji Hospital
M.D. Anderson Cancer Center
Astex Pharmaceuticals, Inc.
Ottawa Hospital Research Institute
Fox Chase Cancer Center
City of Hope Medical Center
University of Utah
University of Nebraska
University Health Network, Toronto
Herlev Hospital
Herlev Hospital